Jump to content
  • Sign Up
  • Join Our Community!

    Get help in our celiac / gluten-free forum.

  • Jefferson Adams
    Jefferson Adams

    Major Financing for HLA-Targeted Autoimmune Therapies Could Lead to New Celiac Treatments

    Reviewed and edited by a celiac disease expert.

      IM Therapeutics announces $10 million in Series A financing to support its new HLA-targeted treatment approach that could lead to treatments for type-1 diabetes, celiac disease, and other autoimmune disorders.


    Caption: Image: CC BY 2.0--Magnus Manske

    Celiac.com 10/23/2019 - Autoimmune therapy company ImmunoMolecular Therapeutics (IM Therapeutics) has received $10 million in Series A financing to support its new HLA-targeted treatment approach to autoimmune diseases, and to develop its lead HLA-targeted drug candidate for type 1 diabetes. 

    Founded by physician scientists at the University of Colorado's Barbara Davis Center for Diabetes, IM Therapeutic creates personalized therapies for autoimmune diseases.

    The company's research has shown that blocking certain high risk human leukocyte antigen (HLA) genes also blocks the subsequent autoimmune response, which offers a possible way to prevent autoimmune triggering in a number of autoimmune diseases.

    Based on that research, the company is creating personalized therapies against HLA targets in various autoimmune diseases, including type 1 diabetes and celiac disease. The company has clinically proven that treating patients based on HLA-DQ8 status can reduce the autoimmune response in type 1 diabetes. 

    With a technology platform that integrates computational chemistry, bioassays, and rational drug design, IM Therapeutics is developing a series of HLA targets for a number of autoimmune diseases.

    IM Therapeutics' personalized therapy approach to treating autoimmune disorders has proven effective in a Phase 1b human study of recently diagnosed type 1 diabetes patients who were positive for the HLA DQ8 variant. 

    The Company is moving forward on its lead oral drug, IMT-002, through IND development for type 1 diabetes, and expanding its therapeutic HLA blocking treatments to other targets of autoimmune disorders, including celiac disease.

    IM Therapeutics’ HLA is currently focused on HLA-DQ8 and DQ2 gene variants, which are known to greatly increase individual risk to both type 1 diabetes and celiac disease. 

    HLA-DQ8 is present in three out of five type 1 diabetes patients, and in one out of ten celiac disease patients. However, about 90% of celiac patients have DQ2, and nearly 100% of celiac patients have DQ2 and/or DQ8.

    “Our value has been clear since day one – getting to the root cause of autoimmunity with a targeted therapy approach and making an impact on diseases such as type 1 diabetes,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. 

    Read more at Businesswire.com


    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,000 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

×
×
  • Create New...